REGMF.US RemeGen Co. Ltd

Healthcare Biotechnology USA Stocks
26.94 USD
Close of Nov 17, 2026
9.54 12.85
Market cap
USD 5.62B
P/E
6.7x
P/B
4.22x
ROE
78.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is REGMF.US undervalued?

Graham number
Price26.94
Graham value24.08
Premium11.9%

REGMF.US trades 11.9% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

RemeGen Co. Ltd fundamental analysis

No fundamental analysis for RemeGen Co. Ltd yet.

RemeGen Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About RemeGen Co. Ltd

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, ur…

Full company profile